Family members of people killed in an attack in Jordan shouldn't be able to proceed with a lawsuit accusing Twitter of encouraging terrorism, the microblogging service argues.
NYS Entity Status
NYS Filing Date
DECEMBER 24, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - DAVID & FAMILY PRODUCTS INC.
AROUND THE WEB
- Twitter Urges Court To Reject Bid To Revive Lawsuit Over ISIS Attack
Wednesday Jun 7, 2017
- ABC News Settles ‘Pink Slime’ Defamation Case With Beef Company
By Mary Beth Quirk - Wednesday Jun 28, 2017
Well, that was quick: Just a few weeks after Beef Products Inc. and ABC News squared off in the opening arguments of the trial over the broadcaster’s use of the phrase “pink slime” to describe an ingredient in some ground beef, the two sides have agreed to put the whole thing to rest.The settlement’s terms are confidential, reports the …
- Time Inc. Moves Into Social Video, Targets GenZ And Millennials With 'The Pretty'
Tuesday Jun 20, 2017
Eager to capture the attention of 16- to-35-year-old beauty enthusiasts, Time Inc. has launched "The Pretty," a new social video brand. What's notable is the all-video approach that offers how-tos,hacks, product information, and entertainment, plus the plan to target both GenZ -- starting at around age 16 -- in addition to Millennials.
- Uber Executive Apologizes for Sexist Remark at Meeting About Company’s Culture
By MIKE ISAAC - Tuesday Jun 13, 2017
When Arianna Huffington discussed research about more women on company boards, David Bonderman said it showed there was “more likely to be more talking.”
- At Goldman, He’s David Solomon. At the Club, He’s D.J. D-Sol.
By KATE KELLY - Thursday Jul 13, 2017
A co-president and a leading contender to become the investment bank’s chief executive has a surprising hobby.
- Insurers Battle Families Over Costly Drug for Fatal Disease
By KATIE THOMAS - Thursday Jun 22, 2017
The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof.